Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
03 December, 2021 06:29 IST
Divi's Laboratories-Yet another consistent quarter despite industry headwinds
Source: IRIS | 09 Aug, 2021, 08.02PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

Divi’s Laboratories (DIVI) delivered in-line 1QFY22 earnings, led by strong off-take in the Custom Synthesis (CS) segment. The backward integration efforts over the past 2-3 years have fructified at a time when peers are facing issues in terms of raw material and logistics cost increases. In fact, this has led to better profitability for the quarter. DIVI remains well poised in terms of both product development and manufacturing capacity to sustain superior return ratios over the next 4-5 years.

Commenting on the result review, Motilal Oswal Institutional Equities said, "We raise our EPS estimate by 5%/4% for FY22/FY23 factoring in a) operational efficiency, b) higher business opportunities in the Sartans portfolio, and c) enhanced growth prospects in the CS segment. We continue to value DIVI at 36x 12M forward earnings to arrive at Target Price of Rs 5,750. We remain positive on DIVI on the back of a) its strong chemistry skill sets driving opportunities in the CS/Generics segment and b) continued cost reduction in production driving market share and profitability. Reiterate Buy."

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.


 Post Comment
Name Email
Security Code type    into this box
Related Articles
Motilal Oswal recommends Buy on TCI; target price of Rs 790 - 02-Dec-2021 13:08
Max Financial Services: Growth to pick up over FY21-26; margin trajectory stable - 02-Dec-2021 12:04
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer